Artrya Converts First SAPPHIRE Participant Into Five-Year US Customer

First SAPPHIRE Participant Becomes Paying Customer

Artrya Limited (ASX:AYA) has turned a clinical relationship into a five-year commercial contract, signing Huntsville Hospital Health System as its first SAPPHIRE Study participant to adopt Salix® for routine clinical use. The agreement makes HH Health Artrya’s fourth US commercial customer and its largest deployment to date.

The contract includes a minimum value of US$0.5 million for Salix Coronary Anatomy, which will generate recurring subscription revenue. That figure excludes additional fee-per-scan revenue from Salix Coronary Plaque and any future revenue from Salix Coronary Flow, making the disclosed minimum a floor for the agreement rather than a full estimate of its potential value.

15-Hospital Network Creates Deployment Test

Salix is expected to be integrated into applicable clinical workflows across HH Health’s 15-hospital network. The announcement does not disclose the rollout timetable, revenue phasing, implementation costs or margins, so the commercial significance will depend partly on how quickly the system moves from contract signing to live usage.

The agreement covers Salix Coronary Anatomy under a non-exclusive software licence, with monthly subscription payments over the five-year term. Coronary Plaque will earn revenue on a fee-per-scan basis and is described as eligible for US reimbursement under a Category I CPT code. Coronary Flow carries the same usage-based model, but its revenue opportunity remains contingent on FDA clearance.

SAPPHIRE Strategy Faces Its First Commercial Test

For Artrya, the most important signal is not simply the contract’s minimum value but the conversion mechanism. The company says SAPPHIRE was designed to build clinical engagement with high-volume US cardiovascular centres while giving participants exposure to Salix. HH Health’s move from research participant to paying customer provides the first disclosed example of that pathway reaching commercial adoption.

Artrya now has four US commercial customers: HH Health, Tanner Health, Northeast Georgia Health System and Cone Health. The next question is whether the company can replicate this conversion with other SAPPHIRE participants while executing a large health-system rollout without allowing deployment complexity to dilute the recurring revenue opportunity.